147 related articles for article (PubMed ID: 27085674)
1. Development of new Malt1 inhibitors and probes.
Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
[TBL] [Abstract][Full Text] [Related]
2. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
[TBL] [Abstract][Full Text] [Related]
3. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
[TBL] [Abstract][Full Text] [Related]
4. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
[TBL] [Abstract][Full Text] [Related]
5. Attacking MALT1 for ABC-DLBCL therapy.
Krappmann D
Oncotarget; 2012 Dec; 3(12):1489-90. PubMed ID: 23455231
[No Abstract] [Full Text] [Related]
6. Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
Lim SM; Jeong Y; Lee S; Im H; Tae HS; Kim BG; Park HD; Park J; Hong S
J Med Chem; 2015 Nov; 58(21):8491-502. PubMed ID: 26496175
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors.
Wu G; Wang H; Zhou W; Zeng B; Mo W; Zhu K; Liu R; Zhou J; Chen C; Chen H
Bioorg Med Chem; 2018 Jul; 26(12):3321-3344. PubMed ID: 29751989
[TBL] [Abstract][Full Text] [Related]
9. Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas.
Eitelhuber AC; Vosyka O; Nagel D; Bognar M; Lenze D; Lammens K; Schlauderer F; Hlahla D; Hopfner KP; Lenz G; Hummel M; Verhelst SH; Krappmann D
Chem Biol; 2015 Jan; 22(1):129-38. PubMed ID: 25556945
[TBL] [Abstract][Full Text] [Related]
10. Peptide-based covalent inhibitors of MALT1 paracaspase.
Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
[TBL] [Abstract][Full Text] [Related]
11. Targeting lymphomas through MALT1 inhibition.
Fontan L; Melnick A
Oncotarget; 2012 Dec; 3(12):1493-4. PubMed ID: 23455603
[No Abstract] [Full Text] [Related]
12. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
13. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
[TBL] [Abstract][Full Text] [Related]
14. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
Liang X; Yu H; Liang R; Feng Z; Saidahmatov A; Sun C; Ren H; Wei X; Zhao J; Yang C; Liu H
J Med Chem; 2024 Feb; 67(4):2884-2906. PubMed ID: 38349664
[TBL] [Abstract][Full Text] [Related]
15. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
Demeyer A; Staal J; Beyaert R
Trends Mol Med; 2016 Feb; 22(2):135-150. PubMed ID: 26787500
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
[TBL] [Abstract][Full Text] [Related]
17. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Safa FM; Rasmussen T; Fontan L; Xia M; Melnick A; Wiestner A; Lobelle-Rich P; Burger JA; Mouawad Y; Safah H; Flemington EK; Saba NS
Haematologica; 2024 May; 109(5):1348-1358. PubMed ID: 37767562
[TBL] [Abstract][Full Text] [Related]
18. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
19. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
